The results of this large study with long-term and prospective follow-up, taken together with earlier findings and the results of the meta-analysis, add further support for the conclusion that the rs266882 polymorphism is unrelated to prostate cancer risk, survival or to plasma PSA levels. The gene discussed is KLK3; the disease is prostate cancer.